Fluorodeoxyglucose-PET in Myocardial Viability and Ischemic Heart Disease.

Authors

Amal Paul, Sandip Basu

Published in

PET clinics. Oct 01, 2026. Epub Oct 01, 2026.

Abstract

Assessment of myocardial viability remains pivotal in managing patients with ischemic cardiomyopathy and left ventricular dysfunction. Fluorine-18 fluorodeoxyglucose (FDG)-PET is the reference standard for evaluating myocardial metabolic viability, enabling identification of dysfunctional yet salvageable myocardium that may benefit from revascularization. This review summarizes the pathophysiological basis, imaging protocols, interpretation strategies, and clinical evidence supporting FDG-PET for myocardial viability assessment. Particular emphasis is placed on recent advancements, including quantitative imaging, hybrid PET/computed tomography and PET/MR imaging systems, artificial intelligence, radiomics, and emerging molecular tracers. Future directions and ongoing challenges in viability imaging are also discussed.

PMID:
42823226
Bibliographic data and abstract were imported from PubMed on 02 Oct 2026.

Read full publication at:
Please sign in to see all details.

Stats

1-terrible, 9-excellent. How would you rate this publication? Sign in in to submit your rating.

Post a comment

You need to be signed in to post comments. You can sign in here.

Comments

There are no comments yet.